Results 11 to 20 of about 10,095 (153)
Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor [PDF]
Yeungnam University Journal of Medicine, 2019 Imatinib mesylate is currently used as the first-line treatment for metastatic gastrointestinal stromal tumors (GISTs). Imatinib-induced hepatotoxicity in patients with GIST is very rare.
Min Kyu Kang +2 more
doaj +1 more source
Blue nails in chronic myeloid leukemia Is it usual?
National Journal of Physiology, Pharmacy and Pharmacology, 2020 Nail toxicity is an uncommon cutaneous adverse effect of imatinib mesylate. Here, we have described a 45-year-old female, a diagnosed case of Philadelphia positive chronic myeloid leukemia, who was on imatinib mesylate for the past 3 months and developed
Jaydeep Raj Damor +7 more
doaj +1 more source
Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience [PDF]
Vojnosanitetski Pregled, 2010 Background/Aim. Imatinib mesylate, a tyrosine kinase inhibitor with specific activity against the breakpoint cluster region - Abelson murine leukemia (BCR-ABL) tyrosine kinase has been developed for treatment of chronic myelogenous leukemia (CML).
Ćojbašić Irena +1 more
doaj +1 more source
PLoS ONE, 2014 Osteosarcoma is the most common primary malignant bone tumour characterized by osteoid production and/or osteolytic lesions of bone. A lack of response to chemotherapeutic treatments shows the importance of exploring new therapeutic methods.
Bérengère Gobin +7 more
doaj +1 more source
Journal of Medical Case Reports, 2011 Introduction Gastrointestinal stromal tumors are a rare neoplasm exhibiting, in most cases, mutations of c-kit. Imatinib mesylate is the standard treatment for patients who have advanced gastrointestinal stromal tumors.
Maazaz Khalid +11 more
doaj +1 more source
Postoperative Cure for Metastatic Gastrointestinal Stromal Tumor
The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2018 Gastrointestinal stromal tumor (GIST) is a mesenchymal tumor derived from Cajal cells originating from the myotonic plexus. The expression of tyrosine kinase (KIT) membrane receptors that are active on KIT is inhibited by the KIT inhibitor imatinib ...
Eun Hyea Park +3 more
doaj +1 more source
SUCCINATE DEHYDROGENASE SUBUNIT B DEFICIENT PEDIATRIC GIST
Hematology, Transfusion and Cell Therapy, 2022 Case report Gastrointestinal stromal tumors (GISTs) occur exceedingly rare in children and adolescents. Eighty five percent of pediatric GISTs and 15 % of adult GISTs lack oncogenic mutations in KIT and PDGFRA.
Melek Yaman Ortakoylu +5 more
doaj +1 more source
BMC Cancer, 2010 Background About 80% of patients with GIST would experience tumor recurrence or metastasis after radical resection. The most common site of the metastasis is the liver. Imatinib mesylate has been proved effective for advanced GIST.
Jiang Ming +4 more
doaj +1 more source
Renal phosphate loss in Iraqi chronic myeloid leukemia patients treated by imatinib mesylate
Iraqi Journal of Hematology, 2020 BACKGROUND: The use of BCR-ABL tyrosine kinase inhibitor imatinib mesylate improved outcomes for patients with chronic myeloid leukemia (CML). Hypophosphatemia is found to be associated with imatinib mesylate use; the exact mechanism of this is not clear
Huda A Al-Taee, Azhar K Athab, Ala Ali
doaj +1 more source
Molecular Therapy: Oncolytics, 2021 Resistance to the BCR-ABL inhibitor imatinib mesylate poses a major problem for the treatment of chronic myeloid leukemia. Imatinib resistance often results from a secondary mutation in BCR-ABL that interferes with drug binding.
Yanjun Liu +8 more
doaj +1 more source